TETRAHYDROIMDIDAZOPYRAZINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS
    6.
    发明授权
    TETRAHYDROIMDIDAZOPYRAZINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS 有权
    四氢嘧啶并咪唑并吡嗪衍生物作为CGRP受体拮抗剂

    公开(公告)号:EP2920173B1

    公开(公告)日:2016-11-23

    申请号:EP13783188.9

    申请日:2013-10-14

    发明人: DEGNAN, Andrew P.

    CPC分类号: C07D487/04

    摘要: The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). [INSERT CHEMICAL STRUCTURE HERE]

    TETRAHYDROIMDIDAZOPYRAZINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS
    7.
    发明公开
    TETRAHYDROIMDIDAZOPYRAZINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS 有权
    四氢嘧啶并咪唑并吡嗪衍生物作为CGRP受体拮抗剂

    公开(公告)号:EP2920173A1

    公开(公告)日:2015-09-23

    申请号:EP13783188.9

    申请日:2013-10-14

    发明人: DEGNAN, Andrew P.

    CPC分类号: C07D487/04

    摘要: The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD). [INSERT CHEMICAL STRUCTURE HERE]

    摘要翻译: 本公开内容总体上涉及式I的新化合物,包括其为CGRP受体拮抗剂的药学上可接受的盐。 本公开还涉及药物组合物和使用所述化合物治疗CGRP相关病症的药物组合物和方法,所述病症包括偏头痛和其他头痛,神经源性血管舒张,神经原性炎症,热损伤,循环休克,与绝经相关的潮红,气道炎性疾病如哮喘, 和慢性阻塞性肺病(COPD)。 [插入此处的化学结构] I